(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of 180.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Abivax Sa's revenue in 2025 is $8,977,906.On average, 8 Wall Street analysts forecast ABVX's revenue for 2025 to be $730,964,501, with the lowest ABVX revenue forecast at $248,601,496, and the highest ABVX revenue forecast at $1,997,690,594. On average, 8 Wall Street analysts forecast ABVX's revenue for 2026 to be $516,418,873, with the lowest ABVX revenue forecast at $248,601,496, and the highest ABVX revenue forecast at $825,712,112.
In 2027, ABVX is forecast to generate $15,821,075,313 in revenue, with the lowest revenue forecast at $5,021,750,221 and the highest revenue forecast at $39,987,423,807.